Research › Fact Sheets › PFE

PFIZER INC

LISTEDNYSE

SYMBOLPFE

SIC2834

STATE OF INC.DE

FISCAL YEAR ENDSDecember 31

CIK78003

PHARMACEUTICAL PREPARATIONS · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2016–2025

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/31/25

($ millions)	Amount	%
Total debt	64,638	42.8
Stockholders' equity	86,476	57.2
Total capitalization	151,114	100.0

5,699,673,589 shares outstanding at 29 July 2026 (cover page of the 10-Q filed 4 August 2026).

LONG-TERM DEBT 12/31/25

($ millions)	Amount
Long-term debt, noncurrent	61,641
Current maturities	2,997
Short-term borrowings / commercial paper	0

CAPITAL STOCK 12/31/25

Common shares authorized	12,000,000,000
Common shares issued	9,621,000,000
Treasury shares	3,935,000,000
Par or stated value per share ($)	0.05
Outstanding at 7/29/26	5,699,673,589

DIVIDENDS DECLARED/PAID

Fiscal year	Per share $	Payout %
2025	1.72	126.5
2024	1.69	119.9
2023	1.65	445.9
2022	1.61	29.4
2021	1.57	40.8

HISTORY AND BUSINESS

HISTORY: Incorporated in Delaware.

BUSINESS: Classified by the SEC under Standard Industrial Classification 2834, Pharmaceutical Preparations. Large accelerated filer. Principal executive office: 66 Hudson Boulevard East, New York, NY 10001-2192. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)	12/31/25	12/31/24	12/31/23
Revenues	62,579	63,627	50,914
Cost of revenues	16,067	17,851	24,954
Research and development	10,437	10,822	10,679
Selling, general and administrative	13,794	14,730	14,771
Depreciation and amortization	6,592	7,013	6,290
Interest expense	2,671	3,091	2,209
Income before income taxes	7,520	8,023	1,058
Income taxes	(266)	(28)	(1,115)
Net income	7,771	8,031	2,119
Earned per share, diluted ($)	1.36	1.41	0.37
Dividends per share ($)	1.72	1.69	1.65

CONSOLIDATED BALANCE SHEET

($ millions)	12/31/25	12/31/24
Cash and equivalents	1,142	1,043
Receivables, net	11,874	11,463
Inventories	10,654	10,851
Total current assets	42,898	50,358
Property, plant and equipment, net	19,317	18,393
Goodwill	71,264	68,527
Total assets	208,160	213,396
Total current liabilities	36,984	42,995
Long-term debt	61,641	57,405
Total liabilities	121,385	124,899
Stockholders' equity	86,476	88,203
Total liabilities and equity	208,160	213,396

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year ended	Revenues	Oper. income	Net income	Net margin %	EPS diluted $	Div. per share $	Oper. cash flow	Capital expend.	Free cash flow	Total assets	Total liabilities	Total debt	Stockholders' equity	ROE %	Debt / equity
12/31/25	62,579	–	7,771	12.4	1.36	1.72	11,704	2,629	9,075	208,160	121,385	64,638	86,476	9.0	0.75
12/31/24	63,627	–	8,031	12.6	1.41	1.69	12,744	2,909	9,835	213,396	124,899	63,605	88,203	9.1	0.72
12/31/23	59,553	–	2,119	3.6	0.37	1.65	8,700	3,907	4,793	226,501	137,213	71,757	89,014	2.4	0.81
12/31/22	101,175	–	31,372	31.0	5.47	1.61	29,267	3,236	26,031	197,205	101,288	35,444	95,661	32.8	0.37
12/31/21	81,288	–	21,979	27.0	3.85	1.57	32,580	2,711	29,869	181,476	104,013	37,831	77,201	28.5	0.49
12/31/20	41,651	–	9,159	22.0	1.63	1.53	14,403	2,226	12,177	154,229	90,756	4,556	63,238	14.5	0.07
12/31/19	40,905	–	16,026	39.2	2.82	1.46	12,588	2,046	10,542	167,594	104,148	51,332	63,143	25.4	0.81
12/31/18	40,825	–	11,153	27.3	1.87	1.38	15,827	1,984	13,843	159,422	95,664	40,785	63,407	17.6	0.64
12/31/17	52,546	–	21,308	40.6	3.52	1.30	16,802	1,956	14,846	171,797	100,141	43,184	71,308	29.9	0.61
12/31/16	52,824	–	7,215	13.7	1.17	1.22	16,192	1,823	14,369	171,615	111,776	37,198	59,544	12.1	0.62

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

PFIZER INC
CIK 78003 · EIN 13-5315170

PRINCIPAL OFFICE:

66 Hudson Boulevard East, New York, NY 10001-2192
Tel.: 2127332323

INCORPORATED:

Delaware

INDUSTRY (SEC SIC CODE):

2834 · Pharmaceutical Preparations

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/31/25, filed 26 February 2026

FORMER NAMES:

PFIZER INC

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

8/4/26	10-Q	period 6/28/26
8/4/26	8-K	period 8/4/26
6/18/26	8-K	period 6/18/26
6/18/26	8-K	period 6/18/26
5/5/26	10-Q	period 3/29/26
5/5/26	8-K	period 5/5/26
4/27/26	8-K	period 4/23/26
3/12/26	DEF 14A	period 4/23/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/26/26) · 10-K FY2024 (filed 2/27/25) · 10-K FY2023 (filed 2/22/24) · 10-K FY2022 (filed 2/23/23) · 10-K FY2021 (filed 2/24/22) · 10-K FY2020 (filed 2/25/21) · 10-K FY2019 (filed 2/27/20) · 10-K FY2018 (filed 2/28/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.